Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Graham, Jessica C ^a   Zarbl, Helmut ^a,b,c  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; EPITOPE; SINGLE STRANDED DNA; TUMOR MARKER;

ADHERENT CELL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING KINETICS; CANCER CELL; CANCER CELL CULTURE; CELL BASED SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; CELL LINE; CELL SURFACE; CELL TRANSFORMATION; COMBINATORIAL CHEMISTRY; HELA CELL; HUMAN; HUMAN CELL; ISOGENIC CELL LINE; MOLECULAR PROBE; NONTUMORIGENIC CELL LINE; PROTEIN ANALYSIS; REVERTANT; SIHA CELL; UTERINE CERVIX CANCER; WART VIRUS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; FEMALE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; VIRUS CELL TRANSFORMATION;

BASE SEQUENCE; BINDING SITES; CELL TRANSFORMATION, VIRAL; DNA, SINGLE-STRANDED; EPITOPES; FEMALE; HELA CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR PROBES; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; PAPILLOMAVIRUS INFECTIONS; SELEX APTAMER TECHNIQUE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84859978206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036103     Document Type: Article

References (37)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of pathology 189: 12-19.
2. Centers for Disease Control and Prevention: Division of Cancer Prevention and Control (2010) Human Papillomavirus (HPV)-Associated Cancers.
3. Liu X, Clements A, Zhao K, Marmorstein R, (2006) Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 281: 578-586.
4. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29: 4294-4301.
5. Kyrgiou M, Shafi M, (2008) HPV Vaccine. Obstet Gynaecol Reprod Med 19: 26-28.
6. Tuerk C, Gold L, (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
7. Ellington AD, Szostak JW, (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
8. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, et al. (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 103: 11838-11843.
9. Shangguan D, Cao ZC, Li Y, Tan W, (2007) Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem 53: 1153-1155.
10. Athanassiou M, Hu Y, Jing L, Houle B, Zarbl H, et al. (1999) Stabilization and reactivation of the p53 tumor suppressor protein in nontumorigenic revertants of HeLa cervical cancer cells. Cell Growth Differ 10: 729-737.
11. Boylan MO, Athanassiou M, Houle B, Wang Y, Zarbl H, (1996) Activation of tumor suppressor genes in nontumorigenic revertants of the HeLa cervical carcinoma cell line. Cell Growth Differ 7: 725-735.
12. Summerhayes IC, Lampidis TJ, Bernal SD, Nadakavukaren JJ, Nadakavukaren KK, et al. (1982) Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci U S A 79: 5292-5296.
13. Zuker M, (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.
14. Morris KN, Jensen KB, Julin CM, Weil M, Gold L, (1998) High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A 95: 2902-2907.
15. Osborne SE, Ellington AD, (1997) Nucleic Acid Selection and the Challenge of Combinatorial Chemistry. Chem Rev 97: 349-370.
16. Nutiu R, Li Y, (2005) In vitro selection of structure-switching signaling aptamers. Angew Chem Int Ed Engl 44: 1061-1065.
17. Wilson DS, Szostak JW, (1999) In vitro selection of functional nucleic acids. Annu Rev Biochem 68: 611-647.
18. Jayasena SD, (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45: 1628-1650.
19. Tang J, Xie J, Shao N, Yan Y, (2006) The DNA aptamers that specifically recognize ricin toxin are selected by two in vitro selection methods. Electrophoresis 27: 1303-1311.
20. Tang J, Yu T, Guo L, Xie J, Shao N, et al. (2007) In vitro selection of DNA aptamer against abrin toxin and aptamer-based abrin direct detection. Biosens Bioelectron 22: 2456-2463.
21. Lee JH, Canny MD, De Erkenez A, Krilleke D, Ng YS, et al. (2005) A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 102: 18902-18907.
22. Hermann T, Patel DJ, (2000) Adaptive recognition by nucleic acid aptamers. Science 287: 820-825.
23. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, et al. (2005) Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 3: e123.
24. Siddiqui MA, Keating GM, (2005) Pegaptanib: in exudative age-related macular degeneration. Drugs 65: 1571-1577; discussion 1578-1579.
25. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, et al. (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747-1757.
26. Ng EW, Adamis AP, (2005) Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40: 352-368.
27. Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, et al. (2006) A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 14: 408-415.
28. Cerchia L, Hamm J, Libri D, Tavitian B, de Franciscis V, (2002) Nucleic acid aptamers in cancer medicine. FEBS Lett 528: 12-16.
29. Cerchia L, de Franciscis V, (2010) Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28: 517-525.
30. Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W, (2008) Applications of aptamers in cancer cell biology. Anal Chim Acta 621: 101-108.
31. Watanabe M, Sheriff S, Lewis KB, Tinch SL, Cho J, et al. (2011) HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines. Cancer Lett.
32. Orava EW, Cicmil N, Gariepy J, (2010) Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta 1798: 2190-2200.
33. Toscano-Garibay JD, Benitez-Hess ML, Alvarez-Salas LM, (2011) Isolation and characterization of an RNA aptamer for the HPV-16 E7 oncoprotein. Arch Med Res 42: 88-96.
34. Laurenson S, Pett MR, Hoppe-Seyler K, Denk C, Hoppe-Seyler F, et al. Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts. Anal Biochem 410: 161-170.
35. Hirt B, (1967) Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 26: 365-369.
36. Musheev MU, Krylov SN, (2006) Selection of aptamers by systematic evolution of ligands by exponential enrichment: addressing the polymerase chain reaction issue. Anal Chim Acta 564: 91-96.
37. Motulsky H, Christopoulos A, (2004) Fitting Models to Biological Data using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting New York Oxford University Press.